Shlomit Jessel

855 total citations
12 papers, 210 citations indexed

About

Shlomit Jessel is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Shlomit Jessel has authored 12 papers receiving a total of 210 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Immunology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Shlomit Jessel's work include Cancer Immunotherapy and Biomarkers (7 papers), CAR-T cell therapy research (5 papers) and Renal cell carcinoma treatment (2 papers). Shlomit Jessel is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), CAR-T cell therapy research (5 papers) and Renal cell carcinoma treatment (2 papers). Shlomit Jessel collaborates with scholars based in United States, Israel and Greece. Shlomit Jessel's co-authors include Harriet M. Kluger, Carmela Felz, Raoul Orvieto, Benjamin Fisch, Ronit Abir, Avi Ben‐Haroush, Sarah A. Weiss, Liliana E. Lucca, Lin Zhang and Michael E. Hurwitz and has published in prestigious journals such as The Journal of Experimental Medicine, Fertility and Sterility and European Journal of Cancer.

In The Last Decade

Shlomit Jessel

12 papers receiving 205 citations

Peers

Shlomit Jessel

ONCOL

PHEOH

IMMUN

Olesya Solheim Norway

Jana Drozenová Czechia

Helena Mörse Sweden

Yibo Dai China

Hélène Vanacker France

Haruka Suzuki Japan

Liz-Anne Lewsley United Kingdom

Pradeep Panuganti United States

Fumitaka Kikkawa Japan

J. van Nagell United States

Olesya Solheim Norway

Shlomit Jessel

57 ×0.6

ONCOL

34 ×0.5

PHEOH

18 ×0.3

IMMUN

102 ×2.0

35 ×0.7

Citations per year, relative to Shlomit Jessel Shlomit Jessel (= 1×) peers Olesya Solheim

Countries citing papers authored by Shlomit Jessel

Since Specialization

Citations

This map shows the geographic impact of Shlomit Jessel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shlomit Jessel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shlomit Jessel more than expected).

Fields of papers citing papers by Shlomit Jessel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shlomit Jessel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shlomit Jessel. The network helps show where Shlomit Jessel may publish in the future.

Co-authorship network of co-authors of Shlomit Jessel

This figure shows the co-authorship network connecting the top 25 collaborators of Shlomit Jessel. A scholar is included among the top collaborators of Shlomit Jessel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shlomit Jessel. Shlomit Jessel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Dizman, Nazlı, Matthew Austin, Bryden Considine, et al.. (2023). Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 21(2). 221–229. 5 indexed citations

Martínez-Morilla, Sandra, Myrto Moutafi, Aileen I. Fernandez, et al.. (2023). Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapy. OncoImmunology. 12(1). 2260618–2260618. 5 indexed citations

Vathiotis, Ioannis, Leonidas Salichos, Sandra Martínez-Morilla, et al.. (2022). Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade. npj Precision Oncology. 6(1). 92–92. 5 indexed citations

Jessel, Shlomit, Sarah A. Weiss, Matthew Austin, et al.. (2022). Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function. Frontiers in Oncology. 12. 836859–836859. 47 indexed citations

Guo, Xiaojia, Shlomit Jessel, Rihao Qu, et al.. (2022). Inhibition of renalase drives tumour rejection by promoting T cell activation. European Journal of Cancer. 165. 81–96. 5 indexed citations

Jessel, Shlomit, Ayesha B. Alvero, Dan‐Arin Silasi, et al.. (2021). Automated Assay of a Four-Protein Biomarker Panel for Improved Detection of Ovarian Cancer. Cancers. 13(2). 325–325. 4 indexed citations

Tran, Thuy, Chetan K. Rane, Christopher R. Zito, et al.. (2021). Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune Cells. Cancers. 13(5). 1049–1049. 9 indexed citations

Jessel, Shlomit, et al.. (2021). Mycophenolate as Primary Treatment for Immune Checkpoint Inhibitor Induced Acute Kidney Injury in a Patient with Concurrent Immunotherapy-Associated Diabetes: A Case Report.. PubMed. 4(1). 10 indexed citations

Jessel, Shlomit, et al.. (2021). Combining the biomarkers macrophage inhibitory factor, osteopontin and prolactin with CA-125 improves early detection of ovarian cancer. Gynecologic Oncology. 162. S115–S116. 1 indexed citations

10.

Lucca, Liliana E., Pierre‐Paul Axisa, Benjamin Y. Lu, et al.. (2020). Circulating clonally expanded T cells reflect functions of tumor-infiltrating T cells. The Journal of Experimental Medicine. 218(4). 45 indexed citations

11.

Jessel, Shlomit, et al.. (2017). Non–Small-cell Lung Cancer Patients With Adenocarcinoma Morphology Have a Better Outcome Compared With Patients Diagnosed With Non–Small-cell Lung Cancer Favor Adenocarcinoma. Clinical Lung Cancer. 18(3). 316–323.e1. 7 indexed citations

12.

Abir, Ronit, Benjamin Fisch, Shlomit Jessel, et al.. (2010). Improving posttransplantation survival of human ovarian tissue by treating the host and graft. Fertility and Sterility. 95(4). 1205–1210. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact